Trials / Completed
CompletedNCT05333289
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
Phase 1/2, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines in Healthy Adults
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 572 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-1030 | Sterile liquid for injection |
| BIOLOGICAL | mRNA-1020 | Sterile liquid for injection |
| BIOLOGICAL | mRNA-1010 | Sterile liquid for injection |
| BIOLOGICAL | Active Comparator | Sterile liquid for injection |
Timeline
- Start date
- 2022-04-06
- Primary completion
- 2022-11-22
- Completion
- 2022-11-22
- First posted
- 2022-04-18
- Last updated
- 2024-02-01
- Results posted
- 2024-02-01
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05333289. Inclusion in this directory is not an endorsement.